Clozapine and other neuroleptic drugs antagonize the light-evoked suppression of melatonin biosynthesis in chick retina: involvement of the D4-like dopamine receptor.
The subtype of dopamine receptor mediating the suppressive effect of light on melatonin biosynthesis in chick retina was characterized pharmacologically. Acute exposure of animals to light during the dark phase of the light-dark cycle dramatically decreased melatonin levels and activity of serotonin N-acetyltransferase (NAT; a key regulatory enzyme in melatonin biosynthetic pathway). Various antagonists of dopamine receptors were tested for their ability to block this action of light on the retinal melatonin formation. Intraocular (i. oc.) pretreatment of chicks with neuroleptic drugs--blockers of the D2-family of dopamine receptors, i.e., clotiapine, clozapine (an atypical neuroleptic with high affinity for a D4-subtype dopamine receptor), haloperidol, spiroperidol, sulpiride, and YM-09151-2, significantly antagonized the light-evoked suppression of the nighttime NAT activity of the chick retina in a dose-dependent manner. In contrast, remoxipride (a D2-selective dopamine antagonist), raclopride and (+)-UH-232 (D2/D3-dopamine receptor antagonists), as well as SCH 23390, a blocker of the D1-family of dopamine receptors, were ineffective. Clozapine, haloperidol, spiroperidol and sulpiride also potently antagonized the suppressive action of light on melatonin content of the chick retina. It is suggested that the dopamine receptor mediating the inhibitory effect of light stimulation on the nighttime melatonin biosynthesis in the retina of chick represents a D4-like subtype.
Zawilska
J B
JB
Department of Biogenic Amines, Polish Academy of Sciences, Lodz.
Derbiszewska
T
T
Nowak
J Z
JZ
D000121:Acetylserotonin O-Methyltransferase / Q000378:metabolism; D000818:Animals; D014150:Antipsychotic Agents / Q000494:pharmacology*; D001191:Arylamine N-Acetyltransferase / Q000037:antagonists & inhibitors; D001552:Benzazepines / Q000494:pharmacology; D002645:Chickens; D003024:Clozapine / Q000494:pharmacology*; D065127:Dopamine D2 Receptor Antagonists; D008027:Light; D008297:Male; D008550:Melatonin / Q000096:biosynthesis*; D011954:Receptors, Dopamine / Q000378:metabolism*; D017447:Receptors, Dopamine D1 / Q000037:antagonists & inhibitors; D050638:Receptors, Dopamine D4; D012160:Retina / Q000201:enzymology / Q000378:metabolism* / Q000528:radiation effects
D014150:Antipsychotic Agents; D001552:Benzazepines; D065127:Dopamine D2 Receptor Antagonists; D011954:Receptors, Dopamine; D017447:Receptors, Dopamine D1; D050638:Receptors, Dopamine D4; D000121:Acetylserotonin O-Methyltransferase; D001191:Arylamine N-Acetyltransferase; D003024:Clozapine; D008550:Melatonin